Introduction: The mechanisms of early filter failure and clotting with different anticoagulation modalities during continuous venovenous hemofiltration (CVVH) are largely unknown. Methods: Citrate, heparin and no anticoagulation were compared. Blood was drawn pre- and post filter up to 720 min. Concentrations of the thrombin-antithrombin (TAT), activated protein C-protein C inhibitor (APC-PCI), and type I plasminogen activator inhibitor (PAI-1) were determined. Results: In case of early filter failure (<24 h), inlet concentrations of TAT and APC-PCI were higher over time, irrespective of anticoagulation. There was more production of APC-PCI and platelet-derived PAI-1 in the filter after 10 min in the heparin group than in other groups. In clotting filters, production of APC-PCI and PAI was also higher with heparin than citrate. Conclusion: Coagulation activation in plasma and inhibition of anticoagulation in plasma and filter may partly determine early CVVH filter failure due to clotting, particularly when heparin is used. Regional anticoagulation by citrate circumvents the inhibition of anticoagulation and fibrinolysis by platelet activation following heparin.

Keywords:
Continuous renal replacement therapy, Anticoagulation, Platelet activation, Filter survival, Citrate versus heparin, Patient outcome, Acute kidney injury
1.
Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Continuous is not continuous: the incidence and impact of circuit ‘down-time' on uraemic control during continuous veno-venous haemofiltration. Intensive Care Med 2003;29:575-578.
2.
Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT: Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis 2000;35:802-811.
3.
Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004;30:260-265.
4.
Nurmohamed SA, Vervloet MG, Girbes AR, Ter Wee PM, Groeneveld AB: Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study. Blood Purif 2007;25:316-323.
5.
Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC: Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011;26:232-239.
6.
Zhang Z, Hongying N: Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012;38:20-28.
7.
Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, Vervloet MG, Beishuizen A, Girbes AR, ter Wee PM, Groeneveld AB: Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care 2014;18:472.
8.
Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009;37:545-552.
9.
Stefanidis I, Hägel J, Frank D, Maurin N: Hemostatic alterations during continuous venovenous hemofiltration in acute renal failure. Clin Nephrol 1996;46:199-205.
10.
Salmon J, Cardigan R, Mackie I, Cohen SL, Machin S, Singer M: Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med 1997;23:38-43.
11.
Cardigan R, McGloin H, Mackie I, Machin S, Singer M: Endothelial dysfunction in critically ill patients: the effect of haemofiltration. Intensive Care Med 1998;24:1264-1271.
12.
Cardigan RA, McGloin H, Mackie IJ, Machin SJ, Singer M: Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int 1999;55:1568-1574.
13.
García-Fernández N, Lavilla FJ, Rocha E, Purroy A: Haemostatic changes in systemic inflammatory response syndrome during continuous renal replacement therapy. J Nephrol 2000;13:282-289.
14.
Opatrný K Jr, Polanská K, Krouzecký A, Vít L, Novák I, Kasal E: The effect of heparin rinse on the biocompatibility of continuous veno-venous hemodiafiltration. Int J Artif Organs 2002;25:520-528.
15.
Bouman CS, de Pont AC, Meijers JC, Bakhtiari K, Roem D, Zeerleder S, Wolbink G, Korevaar JC, Levi M, de Jonge E: The effects of continuous venovenous hemofiltration on coagulation activation. Crit Care 2006;10:R150.
16.
de Pont AC, Bouman CS, Bakhtiari K, Schaap MC, Nieuwland R, Sturk A, Hutten BA, de Jonge E, Vroom MB, Meijers JC, Büller HR: Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO J 2006;52:416-422.
17.
Oudemans-van Straaten HM, van Schilfgaarde M, Molenaar PJ, Wester JP, Leyte A: Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates. Crit Care 2009;13:R193.
18.
Polanská K, Opatrný K Jr, Rokyta R Jr, Krouzecký A, Vit L, Kasal E: Effect of regional citrate anticoagulation on thrombogenicity and biocompatibility during CVVHDF. Ren Fail 2006;28:107-118.
19.
Koyama K, Madoiwa S, Nunomiya S, Koinuma T, Wada M, Sakata A, Ohmori T, Mimuro J, Sakata Y: Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Crit Care 2014;18:R13.
20.
Schilder L, Nurmohamed SA, ter Wee PM, Girbes AR, Beishuizen A, Paauw NJ, Beelen RH, Groeneveld AB: Effect of anticoagulation regimens on handling of interleukin-6 and -8 during continuous venovenous hemofiltration in critically ill patients with acute kidney injury. Cytokine 2012;60:601-607.
21.
Schilder L, Nurmohamed SA, ter Wee PM, Paauw NJ, Girbes AR, Beishuizen A, Beelen RH, Groeneveld AB: Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrol 2014;15:19.
22.
Schilder L, Nurmohamed SA, ter Wee PM, Paauw NJ, Girbes AR, Beishuizen A, Beelen RH, Groeneveld AB: The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Crit Care 2014;18:R78.
23.
Shulman RI, Singer M, Rock J: Continuous renal replacement therapy. Keeping the circuit open: lessons from the lab. Blood Purif 2002;20:275-281.
24.
Yang L, Manithody C, Rezaie AR: Contribution of basic residues of the 70-80-loop to heparin binding and anticoagulant function of activated protein C. Biochemistry 2002;41:6149-6157.
25.
Laurell M, Stenflo J, Carlson TH: Turnover of *I-protein C inhibitor and *I-alpha 1-antitrypsin and their complexes with activated protein C. Blood 1990;76:2290-2295.
26.
Lang IM, Schleef RR: Calcium-dependent stabilization of type I plasminogen activator inhibitor within platelet alpha-granules. J Biol Chem 1996;271:2754-2761.
27.
Gritters M, Grooteman MP, Schoorl M, Schoorl M, Bartels PC, Scheffer PG, Teerlink T, Schalkwijk CG, Spreeuwenberg M, Nubé MJ: Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006;21:153-159.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.